Long non-coding RNA FAM83H-AS1 acts as a potential oncogenic driver in human ovarian cancer

Abstract Background Ovarian cancer (OC) is one of the most aggressive women cancers with increasing incidence and mortality rates worldwide. Long non-coding RNAs (lncRNAs) could as major players in OC process. Although FAM83H antisense RNA1 (FAM83H-AS1) is demonstrated play an important roles in a many cancers, the detailed function and mechanism has not been reported in OC. Methods We integrated multiple kinds of bioinformatics approaches and experiments validated method to evaluate functions of FAM83H-AS1 in OC. Results Some differential expressed lncRNAs were identified between OC and normal control tissues. FAM83H-AS1 was one of most differentially expressed lncRNAs and up-regulated in multiple cancer types. Specially, expression of FAM83H-AS1 was higher in OC and showed difference in diverse stages. High FAM83H-AS1 expression is associated with worse pan-cancer and OC outcomes. FAM83H-AS1-centric network including lncRNA-miRNA, lncRNA-protein and lncRNA-mRNA ceRNA network were constructed to infer the function and mechanism of FAM83H-AS1. There were two methylation sites including cg01399317 and cg20519035 located at FAM83H-AS1. The methylation level of cg01399317 was correlated with gene expression of FAM83H-AS1. The expression level of FAM83H-AS1 was correlated with infiltration level of immune cell including macrophage, neutrphil and dendritic cell in OC patients. Lastly, qRT-PCR showed that the expression of FAM83H-AS1 was higher in OC tissues than normal control tissues. Conclusions Collectively, these results indicated that FAM83H-AS1 may act as an oncogenic driver and it may be a potential therapy target in OC.

Download Full-text

Long non-coding RNA FAM83H-AS1 acts as an oncogenic driver in human ovarian cancer

10.21203/rs.3.rs-18131/v2 ◽

2020 ◽

Cited By ~ 1

Author(s):

Xiaolei Yuan ◽

Ying Huang ◽

Man Guo ◽

Xiaowei Hu ◽

Peiling Li

Keyword(s):

Ovarian Cancer ◽

Normal Control ◽

Immune Cell ◽

Multiple Cancer ◽

Non Coding Rna ◽

Incidence And Mortality ◽

Cancer Types ◽

Oncogenic Driver ◽

Therapy Target ◽

Long Non Coding Rna

Abstract Background Ovarian cancer (OC) is one of the most aggressive women cancers with increasing incidence and mortality rates worldwide. Long non-coding RNAs (lncRNAs) could as major players in OC process. Although FAM83H antisense RNA1 (FAM83H-AS1) is demonstrated play an important roles in a many cancers, the detailed function and mechanism has not been reported in OC. Methods We integrated multiple kinds of bioinformatics approaches and experiments validated method to evaluate functions of FAM83H-AS1 in OC. Results Some differential expressed lncRNAs were identified between OC and normal control tissues. FAM83H-AS1 was one of most differentially expressed lncRNAs and up-regulated in multiple cancer types. Specially, expression of FAM83H-AS1 was higher in OC and showed difference in diverse stages. High FAM83H-AS1 expression is associated with worse pan-cancer and OC outcomes. FAM83H-AS1-centric network including lncRNA-miRNA, lncRNA-protein and lncRNA-mRNA ceRNA network were constructed to infer the function and mechanism of FAM83H-AS1. There were two methylation sites including cg01399317 and cg20519035 located at FAM83H-AS1. The methylation level of cg01399317 was correlated with gene expression of FAM83H-AS1. The expression level of FAM83H-AS1 was correlated with infiltration level of immune cell including macrophage, neutrphil and dendritic cell in OC patients. Lastly, qRT-PCR showed that the expression of FAM83H-AS1 was higher in OC tissues than normal control tissues. Conclusions Collectively, these results indicated that FAM83H-AS1 may act as an oncogenic driver and it may be a potential therapy target in OC.

Download Full-text

Long Non-Coding RNA FAM83H-AS1 Acts as a Potential Oncogenic Driver in Human Ovarian Cancer

10.21203/rs.3.rs-46762/v1 ◽

2020 ◽

Author(s):

Xiaolei Yuan ◽

Ying Huang ◽

Man Guo ◽

Xiaowei Hu ◽

Peiling Li

Keyword(s):

Ovarian Cancer ◽

Normal Control ◽

Immune Cell ◽

Multiple Cancer ◽

Non Coding Rna ◽

Incidence And Mortality ◽

Cancer Types ◽

Oncogenic Driver ◽

Therapy Target ◽

Long Non Coding Rna

Abstract Objective Ovarian cancer (OC) is one of the most aggressive women cancers with increasing incidence and mortality rates worldwide. Long non-coding RNAs (lncRNAs) could as major players in OC process. Although FAM83H antisense RNA1 (FAM83H-AS1) is demonstrated play an important roles in a many cancers, the detailed function and mechanism has not been reported in OC. Results We integrated multiple kinds of bioinformatics approaches and experiments validated method to evaluate functions of FAM83H-AS1 in OC. Some differential expressed lncRNAs were identified between OC and normal control tissues. FAM83H-AS1 was one of most differentially expressed lncRNAs and up-regulated in multiple cancer types. Specially, expression of FAM83H-AS1 was higher in OC and showed difference in diverse stages. High FAM83H-AS1 expression is associated with worse pan-cancer and OC outcomes. FAM83H-AS1-centric network including lncRNA-miRNA, lncRNA-protein and lncRNA-mRNA ceRNA network were constructed to infer the function and mechanism of FAM83H-AS1. There were two methylation sites including cg01399317 and cg20519035 located at FAM83H-AS1. The methylation level of cg01399317 was correlated with gene expression of FAM83H-AS1. The expression level of FAM83H-AS1 was correlated with infiltration level of immune cell including macrophage, neutrphil and dendritic cell in OC patients. Lastly, qRT-PCR showed that the expression of FAM83H-AS1 was higher in OC tissues than normal control tissues. Conclusion Collectively, these results indicated that FAM83H-AS1 may act as an oncogenic driver and it may be a potential therapy target in OC.

Download Full-text

Long non-coding RNA FAM83H-AS1 acts as a potential oncogenic driver in human ovarian cancer

10.21203/rs.3.rs-46762/v2 ◽

2021 ◽

Author(s):

Xiaolei Yuan ◽

Ying Huang ◽

Man Guo ◽

Xiaowei Hu ◽

Peiling Li

Keyword(s):

Ovarian Cancer ◽

Normal Control ◽

Immune Cell ◽

Multiple Cancer ◽

Non Coding Rna ◽

Incidence And Mortality ◽

Cancer Types ◽

Oncogenic Driver ◽

Therapy Target ◽

Long Non Coding Rna

Abstract Objective Ovarian cancer (OC) is one of the most aggressive women cancers with increasing incidence and mortality rates worldwide. Long non-coding RNAs (lncRNAs) could as major players in OC process. Although FAM83H antisense RNA1 (FAM83H-AS1) is demonstrated play an important roles in a many cancers, the detailed function and mechanism has not been reported in OC. Results We integrated multiple kinds of bioinformatics approaches and experiments validated method to evaluate functions of FAM83H-AS1 in OC. Some differential expressed lncRNAs were identified between OC and normal control tissues. FAM83H-AS1 was one of most differentially expressed lncRNAs and up-regulated in multiple cancer types. Specially, expression of FAM83H-AS1 was higher in OC and showed difference in diverse stages. High FAM83H-AS1 expression is associated with worse pan-cancer and OC outcomes. FAM83H-AS1-centric network including lncRNA-miRNA, lncRNA-protein and lncRNA-mRNA ceRNA network were constructed to infer the function and mechanism of FAM83H-AS1. There were two methylation sites including cg01399317 and cg20519035 located at FAM83H-AS1. The methylation level of cg01399317 was correlated with gene expression of FAM83H-AS1. The expression level of FAM83H-AS1 was correlated with infiltration level of immune cell including macrophage, neutrphil and dendritic cell in OC patients. Lastly, qRT-PCR showed that the expression of FAM83H-AS1 was higher in OC tissues than normal control tissues. Conclusion Collectively, these results indicated that FAM83H-AS1 may act as an oncogenic driver and it may be a potential therapy target in OC.

Download Full-text

Identification of cross-talk between m6A/m5C regulators and ferroptosis associated with immune infiltration and prognosis in pan-cancer

10.21203/rs.3.rs-1058834/v1 ◽

2021 ◽

Author(s):

Yingli Zhang

Keyword(s):

Cross Talk ◽

Immune Cell ◽

Epigenetic Modification ◽

Prognostic Significance ◽

Genomic Alteration ◽

Cancer Type ◽

Multiple Cancer ◽

Combination Strategy ◽

Non Coding Rna ◽

Cancer Types

Abstract Although it has been recognized that m6A/5mC methylation and ferroptosis play critical roles in different types of cancers, little is known about the relationship between them. In addition, there is also a growing appreciation that m6A/5mC methylation and ferroptosis may affect immune cell infiltration and activation. This study aimed to reveal the extensive cross-talk between epigenetic modification and ferroptosis. A total of 31 cancer type-specific datasets in TCGA were individually collected by the publicly available web servers for multiple bioinformatic analyses of m6A/5mC regulators and ferroptosis-related genes. Intriguingly, m6A/5mC regulators and ferroptosis-related genes were identified to have considerable global coverage and prognostic significance across multiple cancer types. Moreover, m6A/5mC regulators showed interactive potential with ferroptosis-related genes, and genomic alteration of ferroptosis-related genes coupled with m6A/5mC regulators, at least in pancreatic cancer. Furthermore, m6A/5mC regulators and ferroptosis-related genes were found to be significantly associated with TILs. Finally, m6A/5mC regulators and ferroptosis-related genes exhibited functionally related to each other or co-regulated by TF or non-coding RNA. Together, m6A/5mC methylation and ferroptosis show a wide-ranging connection, and a combination strategy of epigenetic and ferroptosis therapies with ICP inhibitors may benefit more cancer patients in the future.

Download Full-text

Focally amplified long non-coding RNA in epithelial cancer as a potential biomarker and therapeutic target

Biomarkers in Medicine ◽

10.2217/bmm-2021-0455 ◽

2021 ◽

Author(s):

Yahya H Hobani

Keyword(s):

Therapeutic Target ◽

Multiple Cancer ◽

Phosphatase And Tensin Homolog ◽

Tensin Homolog ◽

Non Coding Rna ◽

Potential Biomarker ◽

Noninvasive Biomarker ◽

Cancer Types ◽

Molecular Therapeutic ◽

Long Non Coding Rna

Deregulation of long non-coding RNAs (lncRNAs) has been implicated in tumorigenesis. FALEC is a lncRNA upregulated in multiple cancer types. FALEC functions as an oncogene through various mechanisms, such as competitively binding miRNAs and regulation of PI3K/AKT, Tp53 and phosphatase and tensin homolog signaling pathways. Pertinent to clinical practice, the use of FALEC as a putative biomarker has been identified. These findings suggested that FALEC might play a pivotal role in human cancers. Further studies are warranted to examine the diagnostic and prognostic performance of FALEC as a noninvasive biomarker in liquid biopsy samples and promote its development to be a clinically utilizable prognostic cancer biomarker and molecular therapeutic target.

Download Full-text

LONG NON-CODING RNA AHIF PREDICTS POOR PROGNOSIS IN EPITHELIAL OVARIAN CANCER AND AFFECTS CELL PROLIFERATION THROUGH THE REGULATION OF CELL CYCLE, APOPTOSIS AND SENESCENCE

10.26226/morressier.5770e29cd462b80290b4c0f3 ◽

2016 ◽

Author(s):

junjun qiu

Keyword(s):

Cell Cycle ◽

Ovarian Cancer ◽

Cell Proliferation ◽

Epithelial Ovarian Cancer ◽

Poor Prognosis ◽

Non Coding Rna ◽

Regulation Of Cell Cycle ◽

Long Non Coding Rna

Download Full-text

The long non-coding RNA ‘UCA1’ modulates the response to chemotherapy of ovarian cancer through direct binding to miR-27a-5p and control of UBE2N levels

10.26226/morressier.5ebd45acffea6f735881aea2 ◽

2020 ◽

Author(s):

Matthieu Meryet-Figuiere

Keyword(s):

Ovarian Cancer ◽

Non Coding Rna ◽

Response To Chemotherapy ◽

Direct Binding ◽

And Control ◽

Long Non Coding Rna

Download Full-text

Long non-coding RNA XIST regulates ovarian cancer progression via modulating miR-335/BCL2L2 axis

World Journal of Surgical Oncology ◽

10.1186/s12957-021-02274-7 ◽

2021 ◽

Vol 19 (1) ◽

Author(s):

Qingjuan Meng ◽

Ningning Wang ◽

Guanglan Duan

Keyword(s):

Ovarian Cancer ◽

Cancer Cells ◽

Luciferase Reporter ◽

Migration And Invasion ◽

Ovarian Cancer Cells ◽

Human Ovarian Cancer ◽

Invasion And Migration ◽

Non Coding Rna ◽

And Migration ◽

Long Non Coding Rna

Abstract Background X inactivation-specific transcript (XIST) is the long non-coding RNA (lncRNA) related to cancer, which is involved in the development and progression of various types of tumor. However, up to now, the exact role and molecular mechanism of XIST in the progression of ovarian cancer are not clear. We studied the function of XIST in ovarian cancer cells and clinical tumor specimens. Methods RT-qPCR was performed to detect the expression levels of miR-335 and BCL2L2 in ovarian cancer cells and tissues. MTT and transwell assays were carried out to detect cell proliferation, migration, and invasion abilities. Western blot was performed to analyze the expression level of BCL2L2. The interaction between miR-335 and XIST/BCL2L2 was confirmed using a luciferase reporter assay. Results The inhibition of XIST can inhibit the proliferation invasion and migration of human ovarian cancer cells. In addition, the miR-335/BCL2L2 axis was involved in the functions of XIST in ovarian cancer cells. These results suggested that XIST could regulate tumor proliferation and invasion and migration via modulating miR-335/BCL2L2. Conclusion XIST might be a carcinogenic lncRNA in ovarian cancer by regulating miR-335, and it can serve as a therapeutic target in human ovarian cancer.

Download Full-text